Literature DB >> 6860527

The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension.

M J Serlin, M L Orme, M MacIver, G J Green, R G Sibeon, A M Breckenridge.   

Abstract

1 The effects on heart rate and blood pressure after single and multiple dosing (1 month) of a long acting formulation of propranolol 160 mg daily, and conventional propranolol, 80 mg twice daily, or 160 mg daily were compared in 11 moderately hypertensive subjects previously shown to respond to propranolol. 2 After acute dosing all three treatments produced significant reduction in blood pressure. After multiple dosing all three treatments maintained significant reductions in lying, standing and exercise heart rate and blood pressure throughout the 24 h. At 24 h, after multiple dosing, the fall in resting and standing systolic BP was significantly greater with LA propranolol than with conventional propranolol 80 mg twice daily or conventional propranolol 160 mg once daily (P at least less than 0.05). 3 The plasma propranolol concentration time curve after LA propranolol showed slowed absorption, and the area under the curve was significantly lower than after conventional propranolol (acute dosing; LA propranolol 160 mg 560 mg ml-1 h, conventional propranolol 80 mg twice daily 1135 mg ml-1 h, conventional propranolol 160 mg daily 1414 mg ml-1 h).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6860527      PMCID: PMC1427717          DOI: 10.1111/j.1365-2125.1983.tb02085.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Drug complience in hypertensive patients.

Authors:  A Marshall; D W Barritt
Journal:  Br Med J       Date:  1977-05-14

2.  To be taken as directed.

Authors:  M S Gatley
Journal:  J R Coll Gen Pract       Date:  1968-07

3.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

4.  Pharmacokinetic and pharmacodynamic studies with long-acting propranolol.

Authors:  J McAinsh; N S Baber; R Smith; J Young
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

5.  One and three doses of propranolol a day in hypertension.

Authors:  G van den Brink; P Boer; P van Asten; E J Dorhout Mees; G G Geyskes
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

6.  Treatment of hypertension with propranolol.

Authors:  B N Prichard; P M Gillam
Journal:  Br Med J       Date:  1969-01-04

7.  Beta adrenoreceptor-blocking drugs once daily in essential hypertension: a comparison of propranolol, pindolol and atenolol.

Authors:  J D England
Journal:  Aust N Z J Med       Date:  1981-02

8.  Propranolol in the control of blood pressure: a dose-response study.

Authors:  M J Serlin; M L Orme; N S Baber; R G Sibeon; E Laws; A Breckenridge
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

  8 in total
  13 in total

1.  Hydralazine dose-response curve analysis.

Authors:  D A Graves; K T Muir; W Richards; B W Steiger; I Chang; B Patel
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

2.  Pharmacokinetic and pharmacodynamic comparison of two doses of long acting propranolol (80 and 160 mg) in healthy subjects.

Authors:  B Flouvat; I Berlin; A Cournot; D Robinet; J Duchier; H Sarmini; A Rossi
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

3.  Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.

Authors:  G T McInnes; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Antihypertensive effect and degree of beta-adrenoceptor blockade after short-term and semi-chronic propranolol therapy.

Authors:  F H Leenen; P Boer; E J Dorhout Mees
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

5.  The influence of sodium carboxymethylcellulose on drug release from polyethylene oxide extended release matrices.

Authors:  Dasha Palmer; Marina Levina; Ali Nokhodchi; Dennis Douroumis; Tom Farrell; Ali Rajabi-Siahboomi
Journal:  AAPS PharmSciTech       Date:  2011-06-28       Impact factor: 3.246

6.  Pre-dosing plasma concentrations and beta-adrenoceptor blocking effects during repeated once daily dosing with 160 mg sustained-release propranolol (Inderal LA) and 16/260 oxprenolol Oros to healthy volunteers.

Authors:  J Moppert; P H Degen; A Racine-Poon
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

Review 7.  Pharmacokinetics of long acting propranolol. Implications for therapeutic use.

Authors:  G S Nace; A J Wood
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

8.  CNS-related performance and haemodynamics of metoprolol-Oros and propranolol after single and 3 days dosing in healthy volunteers.

Authors:  A L van Steveninck; M S Pieters; H C Schoemaker; D D Breimer; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

9.  Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations.

Authors:  E Perucca; R Grimaldi; G Gatti; M Caravaggi; F Crema; S Lecchini; G M Frigo
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

10.  The effect of a week's beta-adrenoceptor antagonism on daytime heart-rates, subjective responses to exercise, and physical activity in normal subjects.

Authors:  J M Patrick; H J Wharrad; C G Wilson; A T Birmingham
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.